Viemed Healthcare Announces Voting Results From Its Annual General Meeting of Shareholders

Viemed Healthcare, Inc. (the " Company " or " Viemed ") (NASDAQ:VMD and TSX:VMD.TO), a home medical equipment supplier and the nation's largest independent provider of ventilation that provides post-acute respiratory care services, today announced the voting results from its annual general meeting of shareholders held on June 9, 2022 (the " Meeting ") in Lafayette, Louisiana. The total number of shares represented in person or by proxy at the Meeting was 25,092,560, representing 63.86% of the total issued and outstanding shares in the capital of the Company.

Election of Directors

The eight candidates nominated for election to the Company's Board of Directors (the " Board ") and listed in the Company's management information and proxy circular dated April 29, 2022 (the " Circular "), were elected by at least a majority of the shareholders present in person or represented by proxy at the Meeting. The voting results are as follows:

Name Votes For % For Votes Withheld % Withheld
Casey Hoyt 22,347,069 96.61% 783,691 3.39%
W. Todd Zehnder 22,276,980 96.31% 853,780 3.69%
William Frazier 22,327,086 96.53% 803,674 3.47%
Randy Dobbs 22,746,517 98.34% 384,243 1.66%
Nitin Kaushal 13,939,694 60.26% 9,191,066 39.74%
Timothy Smokoff 21,990,301 95.07% 1,140,459 4.93%
Bruce Greenstein 21,499,058 92.95% 1,631,702 7.05%
Sabrina Heltz 22,237,707 97.23% 893,053 3.86%

Appointment of Auditors

The Company's shareholders have approved the appointment of Ernst & Young LLP as the auditor of the Company for the fiscal year ended December 31, 2022 and authorized the Board to fix the auditor's remuneration.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com.‎

For further information, please contact:‎

Glen Akselrod
Bristol Capital
‎905-326-1888‎
glen@bristolir.com

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.‎
‎337-504-3802‎
investorinfo@viemed.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

VMD:CA,VMD
The Conversation (0)

CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral renal denervation catheter

The Symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral ™ renal denervation (RDN) catheter, used in the Symplicity ™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025 aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
CardieX Limited (ASX:CDX)

CONNEQT Pulse Pre-orders Commence

Cardiex Limited (ASX: CDX) (the Company) is pleased to announce pre-orders for the CONNEQT Arterial Health Assessment, which comes complete with the CONNEQT Pulse vascular biometric monitor, have commenced in the USA.

Keep reading...Show less

Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024 financial results on Thursday, November 7, 2024, prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, November 7, 2024
Time : 8:30 a.m. ET
Telephone : Toll Free: 1-800-836-8184 or International 1-289-819-1350
Webcast   : www.knighttx.com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.
Replay : An archived replay will be available for 30 days at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cardiex Limited

Cardiex September 2024 Quarter Update

Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.
Keep reading...Show less

SPYRAL HTN-ON MED study shows significant, consistent, long-term blood pressure lowering effect at two years

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity™ Spyral renal denervation (RDN) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (ABPM), and office-based systolic blood pressure (OSBP) compared to sham patients at two years. The data were presented as a part of the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT).

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

ACG Presidential Plenary to Highlight Analysis of Xifaxan Risk Reduction of Overt Hepatic Encephalopathy Recurrence

Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizations

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a Presidential Plenary Session of The American College of Gastroenterology® 2024 Annual Scientific Meeting taking place October 25-30 in Philadelphia, PA. This post hoc analysis of data from two randomized trials evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for risk reduction of overt hepatic encephalopathy (OHE) recurrence and all-cause mortality

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Ă—